Study: Hearing, visually impaired adults less likely to be vaccinated for COVID-19

Article

A recent study shows US adults with hearing and visual impairments have lower rates of vaccination for the coronavirus.

A recent cross-sectional study1 shows that COVID-19 vaccination rates are lower among individuals with hearing and visual impairments, compared to those without.

Reported by Kea Turner, PhD, MPH, MA, from the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, and colleagues, the studyincluded adults who participated in the US Census Bureau Household Pulse Survey from April 2021 through March 2022.

The survey collected data on acquisition of the COVID-19 vaccine and determinants of health care access, including demographic and clinical characteristics, as well as social determinants of health, Turner described.

The primary outcome measure was the first COVID-19 vaccine.

The participating patients had difficulty seeing or hearing despite corrective measures or they were blind or deaf.

Assessment of impaired adults

The study included 916, 085 adults (mean age, 54.0 years; 52.0% women), most of whom (82.7%) started the COVID-19 vaccine series.

Compared with adults who were not visually impaired, those with serious visual impairment (mean difference, −6.3%, p <0 .001) and blindness (mean difference, −20.1%, p < 0.001) had lower COVID-19 vaccination rates.

Compared with adults who were not hearing impaired or deaf, adults with serious hearing impairment (mean difference, −2.1%; p =0 .003) and deafness (mean difference, −17.7%, p < 0.001) were less likely to start the COVID-19 vaccine process.

The adults who were the most seriously affected, i.e., those who were blind (p=0.009) or deaf (p=0.003), were less likely to start the series of vaccinations compared with those who were less visually or hearing impaired, respectively.

“The findings of this study suggest that COVID-19 vaccine initiation is lower among adults with vision or hearing disabilities compared with adults without disabilities; this information may inform initiatives to promote equitable and accessible vaccination. Additional research may be needed to monitor COVID-19 vaccination disparities among adults with vision or hearing disabilities and to address disparities,” the investigators concluded.

Reference
1. Turner K, Nguyen OT, Alishahi AM, et al. COVID-19 vaccination rates among US adults with vision or hearing disabilities. JAMA Ophthalmol. Published online August 11, 2022; doi:10.1001/jamaophthalmol.2022.3041

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.